A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising ...

The US Food and Drug Administration (FDA) recently granted fast track designation to Sanofi’s SAR446597 for the treatment of geographic atrophy (GA). 1 ...

Johnson & Johnson (JNJ) gets FDA priority review for TAR-200 gains, a drug releasing system targeting bladder cancer. Read ...

MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their ...

ESMO is proud to announce the inaugural ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025, to be held in Hong Kong SAR, China, from 18–20 July 2025.

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

A promising new treatment to combat "undruggable" cancers has been green-lit for a human trial in 2025. It's hoped the novel drug will be able to stunt the growth and enable the effective ...

Unlike PSMA-targeted agents, 64 Cu-SAR-Bombesin may be particularly valuable for imaging prostate cancer with known biological heterogeneity, which prostate cancer is known to be.

A surgeon can excise breast cancer from the body, but even the most skilled scalpel may not be able to remove every cell—especially when the cells have spread from the original disease site ...

64Cu-SAR-Bombesin targets GRPR, showing efficacy in detecting prostate cancer recurrence in PSMA-negative patients with negative SOC imaging results. The SABRE trial enrolled 53 patients, with 47 ...

Inflammation fuels the high rate of cancer in people over 50, researchers find, leading them to test anti-inflammatories like allergy drugs to fight it.

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug secured approval for a type of kidney cancer in 2023.